Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas
Open Access
- 22 January 2018
- journal article
- editorial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 20 (2) , 151-152
Abstract
See the article by Olmez et al on pages 192–202 .Keywords
Funding Information
- University of Texas MD Anderson Cancer Center
This publication has 11 references indexed in Scilit:
- Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the MicroenvironmentCancer Cell, 2017
- Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alphaNeuro-Oncology, 2017
- Clonal Variation in Drug and Radiation Response among Glioma-Initiating Cells Is Linked to Proneural-Mesenchymal TransitionCell Reports, 2016
- Clonal evolution of glioblastoma under therapyNature Genetics, 2016
- Molecular Pathways: Targeting Diacylglycerol Kinase Alpha in CancerClinical Cancer Research, 2015
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastomaScience, 2014
- A miR-297/hypoxia/DGK-α axis regulating glioblastoma survivalNeuro-Oncology, 2013
- Mesenchymal Differentiation Mediated by NF-κB Promotes Radiation Resistance in GlioblastomaCancer Cell, 2013
- Diacylglycerol Kinase α Is a Critical Signaling Node and Novel Therapeutic Target in Glioblastoma and Other CancersCancer Discovery, 2013
- Role of Diacylglycerol Kinases in T Cell Development and FunctionCritical Reviews in Immunology, 2013